zenuwechografie in de toekomst ?

In Nederland is onderzoek gestart naar het vervangen van de EMG-testen door zenuwechografie. Hopelijk lukt dit in de toekomst, want zo'n EMG -test is draaglijk, maar toch niet zo leuk. Misschien brengt het ook iets meer aan het licht ?

We kunnen de onderzoekers enkel bedanken dat ze toch oog hebben voor onze aandoeningen.

https://www.prinsesbeatrixspierfonds.nl/zenuwechografie-voor-de-diagnose-van-polyneuropathie/

bron : prinses Beatrix spierfonds

uit de kindermond

Opstoot

Komt het door het weer? De kine, die ik deze vakantie oversloeg of de onregelmatig bij het nemen van mijn pillen, maar ik kan weer zo moeilijk uit de voeten. Nu reeds 2 voeten er last van hebben, is staan of wat stappen een "karwei" geworden, zeg maar. Komt daarentegen weer de lage rugpijn erbij en 't is helemaal een ramp. Gevolg : ik beweeg wat minder, wat dan weer niet zo goed is...'de vicieuze cirkel ' . Ik stel me dan ook voortdurend weer de vraag hoe het zal gaan om het schooljaar te beginnen en ik herinner me dat ik vorig jaar zelfde dag , zelfde problemen had...raar, heel raar! En zo blijft een mens voortdurend boren in zichzelf om oorzaken te vinden , maar het brengt me geen figuurlijke stap

de zoektocht begint ...

Bij mijn laatste bezoek aan mijn neuroloog kreeg ik de melding dat hij stopt binnen enkele maanden. Voor veel mensen, maar ook voor mij, is het weer een vertrouwensarts, die ik zie verdwijnen. Voor mij was hij meer dan een "vakman". Ik kon met meer dan mijn "neurologische problemen" bij hem te rade gaan. Vraag is nu : waar vind ik nu een arts, die even goed op de hoogte is van mijn aandoeningen, mijn pathologieën, mijn problemen.
Het wordt van 0 starten, maar ik hoop weer een arts te vinden, die mij in mijn geheel beoordeelt en niet enkel op neurologisch vlak

via BBC-news : hoopvol bericht voor de toekomst , ook van kankerpatiënten

NHS DNA scheme to fight cancer and genetic diseases

By James Gallagher Health editor, BBC News website 

A new genetics project could help "unlock a series of secrets about devastating diseases", the NHS says.

Under the scheme, 11 Genomics Medicine Centres are being set up in English hospitals to gather DNA samples to help devise targeted treatments for a wide range of diseases.
It is focusing on cancer and rare genetic diseases.
The aim is to sequence 100,000 genomes within three years in order to develop new tests and drugs.
Doctors will offer suitable patients the opportunity to take part in the scheme.
They will have to agree to have their genetic code and medical records - stripped of anything that could identify them - made available to drugs companies and researchers.
Up to 25,000 cancer patients will have the genetic code of their healthy tissue compared to the genetic code of their tumour.
A giant game of spot-the-difference will then take place to identify the precise mutations in DNA that are causing a patient's tumour.
This would allow targeted medicines to be developed.
Genetic code Previous genetics research has shown how different cancers can be - for example that breast cancer is not one disease but at least 10 - each with a different cause and life expectancy and each needing a different treatment.
And the development of targeted drugs such as Herceptin - given only if a patient's breast tumour has a certain mutation - has been possible because of genetics research.
Meanwhile, 15,000 patients with rare diseases will have their genome compared with those of their parents and grandparents.
Thousands of genetic diseases - which are individually rare but combined affect large numbers of people - could be identified by finding mistakes in the three billion pairs of letters that make up our genetic code.
The resulting knowledge could give patients an explanation for a disease that has plagued their entire life.
Prof Graeme Black, who will lead the project in Manchester, told the BBC: "It's possible to sequence an individual's entire genetic make-up, their genome, in merely a few days where five years ago that was completely unimaginable.
"Therefore it's possible for conditions where there's a possibility that it's genetic, that we can identify genetic causes much quicker than had been imagined previously."

eindelijk toch ook een adres in Europa !

Gelezen dat een Zwitserse arts zich toch ook onze aandoening onderzoekt. Hij doet wel geen consultaties. Misschien moet ik via An, in Bern, even navraag doen of zij meer kan te weten komen. Ze werkt tenslotte in de medische sector

http://www.mhs.biol.ethz.ch/Research/Suter

men geeft ons toch altijd een sprankeltje hoop

the Brain research foundation publiceerde volgend bericht op hun site :

HNPP

A Study of Provocation and Treatment of HNPP

2008 Seed Grant

Raymond P. Roos, M.D.

University of Chicago

Charcot-Marie Tooth (CMT) comprises a group of inherited peripheral neuropathies. One form of CMT called hereditary liability to pressure palsies (HNPP) is manifest by recurrent episodes of traumatic or compressive peripheral neuropathies.  HNPP is caused by a deletion of a myelin gene called PMP-22.  It is known that vitamin C decreases the expression of PMP-22 and progesterone increases its expression.  The thrust of this application is to investigate whether vitamin C ingestion can influence (and worsen) HNPP clinical disease and whether progesterone can be used as a treatment of HNPP.  The study will test the effect of vitamin C and progesterone treatment on the clinical and pathological disease of an HNPP mouse.

There is presently no treatment of any form of CMT.  The findings of this proposal may have important implications regarding our understanding and treatment of HNPP.  As a result of this study, HNPP patients may be cautioned about excess vitamin C ingestion. In addition, the findings of the present study could lead to a clinical trial with progesterone in HNPP patients.

- See more at: http://www.thebrf.org/Research+Topics/HNPP#sthash.PVVpsBDK.dpuf

HNPP

A Study of Provocation and Treatment of HNPP

2008 Seed Grant

Raymond P. Roos, M.D.

University of Chicago

Charcot-Marie Tooth (CMT) comprises a group of inherited peripheral neuropathies. One form of CMT called hereditary liability to pressure palsies (HNPP) is manifest by recurrent episodes of traumatic or compressive peripheral neuropathies.  HNPP is caused by a deletion of a myelin gene called PMP-22.  It is known that vitamin C decreases the expression of PMP-22 and progesterone increases its expression.  The thrust of this application is to investigate whether vitamin C ingestion can influence (and worsen) HNPP clinical disease and whether progesterone can be used as a treatment of HNPP.  The study will test the effect of vitamin C and progesterone treatment on the clinical and pathological disease of an HNPP mouse.

There is presently no treatment of any form of CMT.  The findings of this proposal may have important implications regarding our understanding and treatment of HNPP.  As a result of this study, HNPP patients may be cautioned about excess vitamin C ingestion. In addition, the findings of the present study could lead to a clinical trial with progesterone in HNPP patients.

- See more at: http://www.thebrf.org/Research+Topics/HNPP#sthash.PVVpsBDK.dpuf

HNPP

A Study of Provocation and Treatment of HNPP

2008 Seed Grant

Raymond P. Roos, M.D.

University of Chicago

Charcot-Marie Tooth (CMT) comprises a group of inherited peripheral neuropathies. One form of CMT called hereditary liability to pressure palsies (HNPP) is manifest by recurrent episodes of traumatic or compressive peripheral neuropathies.  HNPP is caused by a deletion of a myelin gene called PMP-22.  It is known that vitamin C decreases the expression of PMP-22 and progesterone increases its expression.  The thrust of this application is to investigate whether vitamin C ingestion can influence (and worsen) HNPP clinical disease and whether progesterone can be used as a treatment of HNPP.  The study will test the effect of vitamin C and progesterone treatment on the clinical and pathological disease of an HNPP mouse.

There is presently no treatment of any form of CMT.  The findings of this proposal may have important implications regarding our understanding and treatment of HNPP.  As a result of this study, HNPP patients may be cautioned about excess vitamin C ingestion. In addition, the findings of the present study could lead to a clinical trial with progesterone in HNPP patients.

- See more at: http://www.thebrf.org/Research+Topics/HNPP#sthash.PVVpsBDK.dpuf

HNPP

A Study of Provocation and Treatment of HNPP

2008 Seed Grant

Raymond P. Roos, M.D.

University of Chicago

Charcot-Marie Tooth (CMT) comprises a group of inherited peripheral neuropathies. One form of CMT called hereditary liability to pressure palsies (HNPP) is manifest by recurrent episodes of traumatic or compressive peripheral neuropathies.  HNPP is caused by a deletion of a myelin gene called PMP-22.  It is known that vitamin C decreases the expression of PMP-22 and progesterone increases its expression.  The thrust of this application is to investigate whether vitamin C ingestion can influence (and worsen) HNPP clinical disease and whether progesterone can be used as a treatment of HNPP.  The study will test the effect of vitamin C and progesterone treatment on the clinical and pathological disease of an HNPP mouse.

There is presently no treatment of any form of CMT.  The findings of this proposal may have important implications regarding our understanding and treatment of HNPP.  As a result of this study, HNPP patients may be cautioned about excess vitamin C ingestion. In addition, the findings of the present study could lead to a clinical trial with progesterone in HNPP patients.

- See more at: http://www.thebrf.org/Research+Topics/HNPP#sthash.PVVpsBDK.dpuf

HNPP

A Study of Provocation and Treatment of HNPP

2008 Seed Grant

Raymond P. Roos, M.D.

University of Chicago

Charcot-Marie Tooth (CMT) comprises a group of inherited peripheral neuropathies. One form of CMT called hereditary liability to pressure palsies (HNPP) is manifest by recurrent episodes of traumatic or compressive peripheral neuropathies.  HNPP is caused by a deletion of a myelin gene called PMP-22.  It is known that vitamin C decreases the expression of PMP-22 and progesterone increases its expression.  The thrust of this application is to investigate whether vitamin C ingestion can influence (and worsen) HNPP clinical disease and whether progesterone can be used as a treatment of HNPP.  The study will test the effect of vitamin C and progesterone treatment on the clinical and pathological disease of an HNPP mouse.

There is presently no treatment of any form of CMT.  The findings of this proposal may have important implications regarding our understanding and treatment of HNPP.  As a result of this study, HNPP patients may be cautioned about excess vitamin C ingestion. In addition, the findings of the present study could lead to a clinical trial with progesterone in HNPP patients.

- See more at: http://www.thebrf.org/Research+Topics/HNPP#sthash.FgsRs24h.dpuf

HNPP

A Study of Provocation and Treatment of HNPP

2008 Seed Grant

Raymond P. Roos, M.D.

University of Chicago

Charcot-Marie Tooth (CMT) comprises a group of inherited peripheral neuropathies. One form of CMT called hereditary liability to pressure palsies (HNPP) is manifest by recurrent episodes of traumatic or compressive peripheral neuropathies.  HNPP is caused by a deletion of a myelin gene called PMP-22.  It is known that vitamin C decreases the expression of PMP-22 and progesterone increases its expression.  The thrust of this application is to investigate whether vitamin C ingestion can influence (and worsen) HNPP clinical disease and whether progesterone can be used as a treatment of HNPP.  The study will test the effect of vitamin C and progesterone treatment on the clinical and pathological disease of an HNPP mouse.

There is presently no treatment of any form of CMT.  The findings of this proposal may have important implications regarding our understanding and treatment of HNPP.  As a result of this study, HNPP patients may be cautioned about excess vitamin C ingestion. In addition, the findings of the present study could lead to a clinical trial with progesterone in HNPP patients.

- See more at: http://www.thebrf.org/Research+Topics/HNPP#sthash.FgsRs24h.dpuf